Welcome to our dedicated page for Dentsply Sirona SEC filings (Ticker: XRAY), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Finding the R&D spend buried in a 300-page report or tracing how device recalls affect margins can slow any analysis. Dentsply Sirona SEC filings explained simply is exactly what busy investors need.
Our platform ingests every Dentsply Sirona annual report 10-K simplified, Dentsply Sirona quarterly earnings report 10-Q filing, and surprise notice so you see the essentials first. Stock Titan’s AI highlights which product lines—consumables, CAD/CAM, or imaging—drove revenue shifts, and flags any Dentsply Sirona 8-K material events explained within minutes of hitting EDGAR. Need deeper context? Click for a concise Dentsply Sirona earnings report filing analysis that breaks out geographic sales and regulatory commentary.
Monitoring management moves is just as seamless. Receive alerts on Dentsply Sirona insider trading Form 4 transactions and watch Dentsply Sirona Form 4 insider transactions real-time to spot buying or selling patterns before the market reacts. Our dashboards also chart Dentsply Sirona executive stock transactions Form 4 against upcoming product launches, while the latest Dentsply Sirona proxy statement executive compensation is distilled into clear compensation ratios.
Whether you’re understanding Dentsply Sirona SEC documents with AI for a valuation model or verifying compliance disclosures, Stock Titan delivers every filing type—10-K, 10-Q, 8-K, S-8, DEF 14A—backed by AI-powered summaries, keyword search, and real-time updates. Spend less time parsing, and more time deciding.
Dentsply Sirona Inc. (XRAY) – Form 4 insider transaction
Director Jonathan Jay Mazelsky reported the acquisition of 1,561.2862 phantom-stock units on 1 July 2025 under the company’s Directors’ Deferred Compensation plan. Each unit is economically equivalent to one common share and will be settled in stock when the director leaves the board. The derivative units were credited at an indicative price of $16.01 per share, taking Mazelsky’s total deferred-compensation balance to 9,159.0102 units. No open-market cash purchase or sale of common shares was disclosed, and no changes were reported in non-derivative share ownership.
This filing signals continued alignment of the director’s long-term incentives with shareholder value but does not alter the public float or generate immediate dilution. As the grant stems from routine board compensation rather than an active investment decision, market impact is expected to be minimal.
Morgan Stanley Finance LLC, guaranteed by Morgan Stanley, intends to issue Fixed-Income Buffered Auto-Callable Securities linked to the S&P 500 Futures 40% Intraday 4% Decrement VT Index (ticker SPXF40D4). The securities offer a fixed coupon of 7.00%-8.00% per annum paid monthly and mature on 1 August 2030, unless automatically redeemed earlier.
Auto-call feature: beginning 12 months after issuance and on each monthly determination date thereafter, the notes will be redeemed at par (plus the coupon) if the index closes at or above its initial level (100%). Once called, no further payments are due.
Downside protection: at maturity, investors receive full principal repayment so long as the index has not fallen by more than the 15% buffer. Below this threshold, repayment is reduced 1-for-1, exposing holders to up to an 85% maximum loss.
Pricing details: • Pricing date: 28 July 2025 • Settlement/Maturity: 1 Aug 2030 • Estimated value: $920.10 (± $55) per $1,000 face, reflecting issuance costs and Morgan Stanley’s internal models • CUSIP: 61778NBH3
Key risks called out by the issuer
- No participation in any index appreciation beyond par.
- Potential early redemption limits total coupon receipts.
- Full exposure to Morgan Stanley credit risk; MSFL has no independent assets.
- Index-specific risks: 4% annual decrement drag, leverage, short operating history (inception 30 Aug 2024).
Tax treatment and other detailed structural provisions are summarized in the preliminary pricing supplement (SEC link provided) and should be reviewed before investing.
FAQ
What is the current stock price of Dentsply Sirona (XRAY)?
What is the market cap of Dentsply Sirona (XRAY)?
What is Dentsply Sirona's primary business?
How does Dentsply Sirona generate its revenue?
What business segments does the company operate in?
How does Dentsply Sirona differentiate itself from competitors?
What are the company’s key distribution channels?
How does the company ensure quality and regulatory compliance?
What is the significance of the company’s merger history?
What role does innovation play in the company's strategy?
